IP Library Granted Patent US 9,097,728
Granted Patent B2
US 9,097,728 · App. 13/265,898 · Granted Aug 4, 2015

Method for diagnosing a hemoglobin-related disorder

Inventors: Veronique Baudin-Creuza (Le Kremlin-Bicetre, FR); Corinne Vasseur (Le Kremlin-Bicetre, FR); Frederic Galacteros (Creteil, FR)
Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM); Universite Paris-Sud; Assistance Publique-Hopitaux de Paris; Universite Paris Est Creteil Val de Marne
G01N33/721G01N33/53G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,097,728
App. No.
13/265,898
Granted
Aug 4, 2015
Kind
B2
Abstract

A method for diagnosing and/or staging a hemoglobin disorder such as β-thalassemia involves contacting a blood sample of a subject with an Alpha-Hemoglobin Stabilizing Protein which may be present on a solid support, and detecting and/or quantifying free α-Hb. Detection or quantification can be achieved by photometry such as HTRF or immunological procedures such as EIA and ELISA. The free α-Hb is compared to a reference value, and can be used to correlate with the diagnosis and/or staging of the hemoglobin disorder for the subject.

Claims (5)

1. A method for diagnosing and/or staging β-thalassemia in a subject in need thereof, said method comprising:

contacting a blood sample obtained from said subject with Alpha-Hemoglobin Stabilizing Protein (AHSP),

detecting and/or quantifying the presence of free monomeric α-Hb in said blood sample by using at least one labelled antibody that binds specifically to α-Hb,

comparing an amount of free monomeric α-Hb detected and/or quantified in said detecting and/or quantifying step with a reference value, wherein said reference value comprises the amount of free monomeric α-Hb detected and/or quantified in at least one control subject not diagnosed with a hemoglobin disorder; and

correlating said amount of free monomeric α-Hb with the diagnosis and/or the staging of a hemoglobin disorder in said subject, wherein significantly higher amounts of said free monomeric α-Hb detected and/or quantified in said subject as compared to said reference value corresponds to the severity of β-thalassemia in said subject.

Assignments (3)
MERGER Recorded Aug 17, 2022
From: UNIVERSITE PARIS-SUD
To: UNIVERSITÉ PARIS-SACLAY
Reel/Frame 060831/0318 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2015
From: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE PARIS-SUD; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS; UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
Reel/Frame 035823/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2011
From: BAUDIN-CREUZA, VERONIQUE; VASSEUR, CORINNE; GALACTEROS, FREDERIC
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Reel/Frame 027256/0338 →
Priority Claims (1)
EP 09305352 · Apr 24, 2009 · regional
Continuity (1)
Related Publication 20120052516A1 · Mar 1, 2012